Author Interviews, Cancer Research, Dermatology, Radiation Therapy / 23.02.2019
Superficial Radiation Therapy For Non-Melanoma Skin Cancers in the Elderly
MedicalResearch.com Interview with:
[caption id="attachment_47622" align="alignleft" width="145"]
Dr. Roth[/caption]
William I. Roth MD
Dermatology and Dermatological Surgery
Boynton Beach, FL
MedicalResearch.com: What is the background for this study?
Dr. Roth[/caption]
William I. Roth MD
Dermatology and Dermatological Surgery
Boynton Beach, FL
MedicalResearch.com: What is the background for this study?
- This retrospective study reviewed medical records of patients with biopsy-proven, primary cutaneous basal and squamous cell carcinoma (BCC and SCC) lesions on the lower extremities. These patients were treated with the Sensus Healthcare’s Superficial Radiation Therapy SRT-100 Unit between 2011 and 2014. The SRT-100 is most amenable for treating non-melanoma skin cancer (NMSC) in patients aged 65 and older although many younger patients are treated as well when a non-scarring method is desired.
- The types of skin cancers treated included superficial, well differentiated and moderately differentiated squamous cell carcinomas, squamous cell carcinoma in situ and basal cell carcinomas including infiltrative basal cell carcinomas. Higher energy linear accelerator radiation units have been reported to have a high incidence of healing problems. With the SRT-100 the radiation is concentrated primarily in the higher layers of the skin where the skin cancer is located and thus the treatments are well tolerated.
Dr. Immler[/caption]
Dr Simone Immler PhD
School of Biological Sciences
University of East Anglia
MedicalResearch.com: What is the background for this study?
Response: Sperm produced by one male vary substantially both in their genetic content as well as their swimming ability including speed and duration. In a previous study in the zebrafish, we showed that sperm swimming duration is at least partly determined by the underlying haploid genetic content carried by the different sperm within an ejaculate (alavioon et al. 2017 PNAS). If sperm with different swimming ability differ in their genetic content, we expect to see differences among the offspring sired by sperm that vary on their swimming ability.
In our new study, we tested how selection on sperm swimming duration affects offspring fitness. We performed in vitro fertilisation assays mimicking natural conditions in the externally fertilising zebrafish. We split the ejaculate of one male into two halves and in one half we added the sperm straight away to the eggs, allowing all motile sperm to have a go at fertilising an egg. In the second half, we activated the sperm but delayed the moment of fertilisation by 25 seconds and thus selected for the longer swimming sperm. In this treatment only sperm that were still swimming after this period of time (about 50%) were able to fertilise an egg.
We then reared the offspring to adulthood and measured number of offspring produced throughout life and measured lifespan. We found that sperm that were able to swim for longer sired offspring that not only produced more and healthier offspring but also lived for longer than their full siblings sired by sperm with reduced swimming ability. Our previous research (Alavioon et al. 2017 PNAS) suggests that these differences are caused at least partly by genetic differences among sperm.
Dr. Kitchener[/caption]
Professor Henry Kitchener, MD FRCOG FRCS
University of Manchester, Manchester, UK
MedicalResearch.com: What is the background for this study?
Response: We now have reliable and affordable technologies to detect human papillomavirus (HPV), a virus which is universally accepted as the cause of cervical cancer. Various large trials confirmed that cervical screening could be improved by replacing the smear (cytology) test that has been in use for decades, with HPV testing. Many countries are now making the switch. In England, this is planned for the end of 2019. To test how to run HPV testing within the English National Health Service, a pilot was initiated in 2013 in six screening laboratories. We also wanted to determine whether the encouraging findings from the trials could be translated to everyday practice. This is important not only because we will be using different HPV tests, but also because women undergoing screening in trials are much more selected than those who are invited to population-based screening.